LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
113.38
+1.02 (+0.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close112.36
Open112.63
Bid112.83 x 1100
Ask116.98 x 900
Day's Range111.82 - 114.23
52 Week Range98.56 - 278.62
Volume143,662
Avg. Volume461,423
Market Cap2.222B
Beta (3Y Monthly)1.73
PE Ratio (TTM)3.44
EPS (TTM)32.97
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-07-02
1y Target Est202.40
  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks6 days ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Business Wire9 days ago

    Ligand Licenses VER250840 to Cumulus Oncology

    Ligand Pharmaceuticals Incorporated (LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in the mid-to-high single digit range, depending on revenue. In addition, Ligand is eligible to receive an additional fee, payable in cash or Cumulus equity, upon Cumulus achieving specified financing-related events.

  • GuruFocus.com11 days ago

    Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares

    CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 05/14/2019 at an average price of $113.5 a share.

  • A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE
    Simply Wall St.16 days ago

    A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
    Zacks17 days ago

    AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

    AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

  • Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
    Zacks18 days ago

    Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

    Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of LGND earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 Ligand Pharmaceuticals Inc Earnings Call

  • Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
    Zacks19 days ago

    Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

    Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

  • Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
    Zacks19 days ago

    Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1

    Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

  • Markit19 days ago

    See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.

    Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding LGND are favorable, with net inflows of $3.59 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Novan adds more cash, now confident it can execute
    American City Business Journals20 days ago

    Novan adds more cash, now confident it can execute

    In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.

  • Business Wire20 days ago

    Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

    Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all expenses to develop or commercialize SB206, and will use 100% of the proceeds from this transaction in the development and pursuit of regulatory approval for SB206.

  • GlobeNewswire20 days ago

    Novan Completes Funding Transaction with Ligand Pharmaceuticals

    Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.

  • Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
    Zacks23 days ago

    Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down

    Ligand (LGND) first-quarter earnings and sales decrease year over year.

  • Benzinga23 days ago

    The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...

  • Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript
    Motley Fool23 days ago

    Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript

    LGND earnings call for the period ending March 30, 2019.

  • Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
    Zacks24 days ago

    Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

    Ligand (LGND) delivered earnings and revenue surprises of -95.92% and 13.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press24 days ago

    Ligand: 1Q Earnings Snapshot

    The San Diego-based company said it had profit of $31.32 per share. Earnings, adjusted for one-time gains and costs, came to $1.16 per share. The drugmaker posted revenue of $43.5 million in the period. ...

  • Business Wire24 days ago

    Ligand Reports First Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today

  • Business Wire24 days ago

    Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Ligand Pharmaceuticals Incorporated (LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.

  • Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
    Insider Monkey27 days ago

    Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]

  • Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth
    Zackslast month

    Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 5 Top Biotech Stocks to Buy in 2019
    Motley Foollast month

    5 Top Biotech Stocks to Buy in 2019

    Looking for potential winning biotech stocks? These five check off all the boxes for investors.

  • Business Wirelast month

    Ligand to Report First Quarter 2019 Results on May 2nd

    Ligand Pharmaceuticals Incorporated announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.